Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials

3336 results

Sort By:

SOS for Caregiver Wellbeing

Study ID: NCT07136584
Start Date: 2025-10-15
End Date: 2026-04-28
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

100

Intervention / Treatment

Screening, Outcomes and Referral Pathways

Sponsor

Murdoch Childrens Research Institute

Source: clinicaltrials.gov

Share:
Add to list

A Study of Surgery and Radiotherapy in People With Breast Cancer

Study ID: NCT07053085
Start Date: 2026-07-15
End Date: 2028-07
Study Type

Interventional

Study Phase

Phase2

No. of Participants

162

Intervention / Treatment

Lumpectomy or mastectomy

Radiotherapy

Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Allopregnanolone in Chronic Complex Traumatic Brain Injury

Study ID: NCT04003285
Start Date: 2026-02-01
End Date: 2027-02-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

132

Intervention / Treatment

Placebo

Allopregnanolone

Allopregnanolone

Sponsor

VA Office of Research and Development

Source: clinicaltrials.gov

Share:
Add to list

Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

Study ID: NCT06675123
Start Date: 2025-11-01
End Date: 2026-11-01
Study Type

Interventional

Study Phase

Phase1

No. of Participants

10

Intervention / Treatment

Biopsy

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

BTK inhibitor

Computed Tomography

Pacritinib

Positron Emission Tomography

Sponsor

City of Hope Medical Center

Source: clinicaltrials.gov

Share:
Add to list

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

Study ID: NCT07015996
Start Date: 2025-09-16
End Date: 2028-09-16
Study Type

Interventional

Study Phase

Phase2

No. of Participants

62

Intervention / Treatment

TEZEPELUMAB

Peanut Oral Immunotherapy (OIT)

Placebo for Tezepelumab

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Source: clinicaltrials.gov

Share:
Add to list

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Study ID: NCT06364904
Start Date: 2025-10
End Date: 2029-04-15
Study Type

Interventional

Study Phase

Phase3

No. of Participants

210

Intervention / Treatment

Tislelizumab, Cisplatin, Gemcitabine and Trilaciclib

Tislelizumab, Cisplatin, Gemcitabine

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Source: clinicaltrials.gov

Share:
Add to list

Glucose Levels in Acute Pancreatitis and the Impact of Insulin Depletion and Bacterial Endotoxaemia

Study ID: NCT06972238
Start Date: 2025-12-01
End Date: 2026-08-30
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

30

Intervention / Treatment
Sponsor

Manchester University NHS Foundation Trust

Source: clinicaltrials.gov

Share:
Add to list

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

Study ID: NCT05341947
Start Date: 2026-06
End Date: 2027-12
Study Type

Interventional

Study Phase

Phase1

No. of Participants

10

Intervention / Treatment

Activated T cells

Sponsor

Jeremy Rudnick, M.D

Source: clinicaltrials.gov

Share:
Add to list

SENTInel Node Mapping Versus Comprehensive Lymphadenectomy in P53-Mutated Endometrial Cancer: a Non-Inferiority Randomized Trial

Study ID: NCT06900582
Start Date: 2025-10
End Date: 2031-10
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

374

Intervention / Treatment

Sentinel Lymph Node Mapping

Comprehensive pelvic and para-aortic lymphadenectomy

Sponsor

University Hospital, Strasbourg, France

Source: clinicaltrials.gov

Share:
Add to list

Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax

Study ID: NCT03569514
Start Date: 2025-11-30
End Date: 2026-07
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

10

Intervention / Treatment

AIGIV

Sponsor

Emergent BioSolutions

Source: clinicaltrials.gov

Share:
Add to list